BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the 36 th Annual Deutsche Bank Health Care Conference to be held at the InterContinental Hotel, Boston from May 2-4, 2011.

Phillip B. Donenberg, BioSante’s senior vice president, finance & CFO, will speak on Tuesday May 3, 2011 at 4:10 pm EDT. He will provide an overview of the company, as well as an update on the LibiGel ® (testosterone gel) Phase III clinical development program.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante’s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA has been filed with a PDUFA date of November 14, 2011, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at:

Copyright Business Wire 2010